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We examined the functional characteristics of choline uptake in human tongue carcinoma using the cell
line HSC-3. Furthermore, we explored the possible correlation between the inhibition of choline uptake
and apoptotic cell death. Both choline transporter-like protein 1 (CTL1) and CTL2 mRNAs and proteins
were expressed, and were located in plasma membrane and mitochondria, respectively. Choline uptake
was saturable and mediated by a single transport system, which is pH-dependent. Several cationic drugs
inhibited cell viability and [3H]choline uptake. Choline uptake inhibitors and choline deﬁciency inhibited
cell viability and increased caspase-3/7 activity. We conclude that extracellular choline is mainly
transported via a CTL1 that relies on a directed Hþ gradient as a driving force. The functional inhibition of
CTL1 by cationic drugs could promote apoptotic cell death. Furthermore, CTL2 may be the major site for
the control of choline oxidation in mitochondria and hence for the supply of endogenous betaine and S-
adenosyl methionine, which serves as a major methyl donor. Identiﬁcation of this CTL1- and CTL2-
mediated choline transport system provides a potential new target for tongue cancer therapy.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Choline is an essential nutrient for all cells, and is needed for the
synthesis of the major membrane phospholipids phosphatidyl-
choline (PC) and sphingomyelin. Large degrees of choline uptake
and PC biosynthesis are necessary for new membrane synthesis.
Choline is also used as a precursor for the neurotransmitter
acetylcholine (ACh) and betaine, and participates in several vital
biological functions. Betaine, an oxidized metabolite of choline, is a
source of methyl groups for the production of S-adenosyl methio-
nine (SAM), which serves as a substrate for DNA and histone
methyltransferases, and is thus required for the establishment and
maintenance of the epigenome (1). Epigenetic mechanisms play
important roles in carcinogenesis. Aberrant DNA methylation ise, Tokyo Medical University,
an. Tel.: þ81 3 3351 6141;
.
rmacological Society.
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d/4.0/).observed in tongue squamous cell carcinoma (TSCC) tissue and
plays an important role in the tumorigenesis, development and
progression of TSCC (2). Previous studies have demonstrated ab-
normalities in choline uptake and choline phospholipid meta-
bolism in tongue cancer based on imaging with magnetic
resonance spectroscopy (MRS) (3). Furthermore, positron emission
tomography (PET) and PET computed tomography (PET-CT) studies
with 11C-labeled choline are used in tongue cancer patients (4). The
aberrant choline metabolism in cancer cells is strongly correlated
with the progression of malignancy (5e7). Thus, the intracellular
accumulation of choline through choline transporters is the rate-
limiting step in choline phospholipid metabolism, and a prerequi-
site for cancer cell proliferation. However, the uptake system for
choline and the functional expression of choline transporters in
tongue cancer are not totally understood.
The choline transport system has been categorized into three
transporter families: high-afﬁnity choline transporter 1 (CHT1/
SLC5A7), intermediate-afﬁnity choline transporter-like proteins
(CTL1-5/SLC44A1-5), and polyspeciﬁc organic cation transporters
(OCT1-2/SLC22A1-2) that exhibit lowafﬁnity for choline (8,9). CHT1nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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bepart of the rate-limiting step inACh synthesis. In addition, CHT1 is
a Naþ-dependent co-transporter that is highly sensitive to the
choline analogue hemicholinium-3 (HC-3) in the nM range. Choline
is known tobe a substrate for carriers ofOCTs, and these transporters
accept choline as a substrate with comparatively low afﬁnity.
Recently, distinct choline transporters called CTLs have been shown
to be present in various human tissues (10,11). CTL1 is a Naþ-inde-
pendent, intermediate-afﬁnity transporter of choline that can be
completely inhibited by a high concentration of HC-3 in the mM
range. CTL2 is expressed as two isoforms (CTL2-P1 and CTL2-P2) in
the cochlea, tongue, heart, colon, lung, kidney, liver and spleen,
which suggests that tissue-speciﬁc differences may inﬂuence its
function in each tissue. While human CTL2-P1 does not transport
choline, human CTL2-P2 exhibits detectable choline transport ac-
tivity (12). However, the functions of other transporters in this
family (CTL3-5) are not fully understood. They are expressed in
different organisms and cell types, and this implies that they are
important for choline transport for a broader purpose, such as
phospholipid synthesis and epigenetics.
In this study, we examined the functional characteristics of
choline uptake and sought to identify the transporters that mediate
choline uptake in the tongue cancer cell line HSC-3. We also
examined the effects of existing drugs on choline uptake and cell
viability, to investigate the possible beneﬁts of drug repositioning.
2. Materials and methods
2.1. Materials
The human tongue cancer cell line HSC-3 was provided by the
JCRBCell Bank (Osaka, Japan). [3H]Choline chloride (speciﬁc activity:
3182 GBq/mmol) was obtained from PerkinElmer Life Sciences, Inc.
(Boston, MA, USA). A QIA shredder and RNeasy Mini Kit were ob-
tained fromQiagen Inc. (Valencia, CA,USA).ATaqMan®RNA-to-CT™
1-StepKit andTaqMan®GeneExpressionAssayswereobtained from
Applied Biosystems (Foster City, CA, USA). Detector Blocking Solu-
tion, Wash Solution, and horseradish peroxidase-conjugated anti-
rabbit and anti-mouse IgG were purchased from Kirkegaard and
Perry Laboratories Inc. (Gaithersburg, MD, USA). VECTASHIELD
mountingmediumwith 40, 6-diamidino-2-phenylindole (DAPI)was
purchased from Vector Laboratories, Inc. (Burlingame, CA, USA).
Alexa Fluor 488goat anti-rabbit andanti-mouse IgG, andAlexa Fluor
568 goat anti-rabbit and anti-mouse IgG were purchased from
Molecular Probes Inc. (Eugene, OR, USA). RIPA Lysis Buffer System
(sc-24948) was purchased from Santa Cruz Biotechnology, Inc.
(Dallas, TX, USA). Tris-SDS b-ME sample solution was purchased
from Cosmo Bio Corporation (Tokyo, Japan). Protein Multicolor III
was purchased from BioDynamics Laboratory Inc. (Tokyo, Japan). A
DC Protein Assay kit, Mini-PROTEAN® TGX™ Gel and Trans-Blot®
Turbo™ Transfer Pack were purchased from Bio-Rad Laboratories
(Tokyo, Japan). Anti-CTL1 polyclonal antibody (ab110767), anti-pan
Cadherin antibody (CH-19, ab6528) and anti-COX IV antibody
(ab16056) were purchased from Abcam plc (Cambridge, UK). Anti-
CTL2 monoclonal antibody (clone 3D11), which recognizes both
CTL2-P1 and CTL2-P2, was purchased from Abnova Corporation
(Taipei, Taiwan). Anti-Calnexin antibody (PM060MS) and anti-
MG130 antibody (PM061) were purchased from Medical Biological
Laboratories Co., LTD. (Nagoya, Japan). ATPLite™ was purchased
from PerkinElmer Life and Analytical Sciences (Boston, MA, USA).
Caspase-Glo® 3/7 Assay was purchased from Promega Corporation
(Madison, WI, USA). Alimemazine tartrate, hydroxyzine dihydro-
chloride, ketotifen fumarate, azelastine hydrochloride and ebastine
were purchased from Funakoshi Co., Ltd. (Tokyo, Japan). Choline
chloride and RPMI 1640 medium, clemastine fumarate,mequitazine, oxatomide and D-MEMmediumwere purchased from
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Homo-
chlorcyclizine hydrochloride, cyproheptadine hydrochloride, par-
oxetine hydrochloride, quinidine hydrochloride, mebendazole,
bepridil hydrochloride, lomerizine dihydrochloride, HC-3, Triton X-
100, N-methyl-D-glucamine (NMDG), 2-amino-2-(hydroxymethyl)-
1,3-propanediol (Tris), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) and 2-(N-morpholino)
ethanesulfonic acid (MES) were purchased from SigmaeAldrich Co.
LLC. (St. Louis, MO, USA). Promethazine hydrochloride, loratadine,
levocetirizine dihydrochloride, and tranilast were purchased from
Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Rupatadine
fumarate was purchased from COSMO BIO Co., Ltd. (Tokyo, Japan).
Citalopram hydrobromide and ﬂuoxetine hydrochloride were pur-
chased from LKT Laboratories, Inc. (St Paul, MN, USA). Reboxetine
mesylate was purchased from Cayman Chemical Company (Ann
Arbor,MI, USA). Fluvoxaminemaleatewas a generous gift fromMeiji
Yakuhin Co., Ltd. (Tokyo, Japan). D-MEM medium without choline
chloridewas obtained from Cell Science& Technology Institute, Inc.
(Miyagi, Japan).
2.2. Cell culture
HSC-3 cells were grown in RPMI 1640 medium supplemented
with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and
20 mg/L kanamycin (Gibco) on non-coated ﬂasks and in 24-well
plates. Cultures were maintained in a humidiﬁed atmosphere of 5%
CO2 and 95% air at 37 C, and the medium was changed every 3e4
days.
2.3. [3H]Choline uptake into HSC-3 cells
Cells were cultured in 24-well culture plates. The growth me-
dium was removed from the 24-well culture plates. Cells were
washed twice with uptake buffer, consisting of 125 mM NaCl,
4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 5.6 mM glucose, 1.2 mM
MgSO4 and 25 mM HEPES adjusted to pH 7.4 with Tris. This was
followed by the addition of [3H]choline. Choline uptake was
terminated by removal of the uptake buffer and three rapid washes
with ice-cold uptake buffer. The cultures were dissolved in 0.1 N
NaOH and 0.1% Triton X-100, and aliquots were taken for liquid
scintillation counting and protein assay. Radioactivity was
measured by a liquid scintillation counter (Tri-Carb® 2100 TR,
Packard, USA). When Naþ-free buffer was used, the Naþ-free buffer
was modiﬁed by replacing NaCl with an equimolar concentration of
NMDG chloride. Uptake buffers with different pH values (pH 6.0,
6.5, 7.0, 7.5, 8.0 and 8.5) were prepared by mixing 25 mMMES (pH
5.5) and 25 mM Tris (pH 8.5). Both buffers contained 125 mM NaCl,
4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 5.6 mM glucose and
1.2 mM MgSO4. In experiments on saturation kinetics, the con-
centration of [3H]cholinewas kept constant at 10 nM and unlabeled
choline was added to give the desired choline concentration. The
speciﬁc uptake of [3H]choline was calculated as the difference be-
tween total [3H]choline uptake in the presence and absence of
30 mM unlabeled choline. Protein concentrations were determined
using a DC Protein Assay Kit.
2.4. RNA extraction and real-time polymerase chain reaction (PCR)
assay
Cells were washed with sterile D-PBS and total RNA was
extracted from the cells using QIA shredder and an RNeasy Mini Kit
according to themanufacturer's instructions. The TaqManprobes for
the target mRNAs (CHT1, OCT1-3, CTL1-5 and the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH)) were
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Expression Assays. For one-step real-time PCR, 50 ng of total RNA
was added to a master mixture by using the TaqMan® RNA-to-CT™
1-Step Kit according to the manufacturer's instructions. Real-time
PCR data were analyzed with the Applied Biosystems StepOne
Plus™ Real-Time PCR system. The relative mRNA expression levels
of the target genes in cells were calculated using the comparative
cycle time (Ct) method. The mRNA expression level relative to
GAPDH for each target PCR was calculated using the following
equation: relativemRNAexpression¼ 2  (Ct target  Ct GAPDH) 100%.
2.5. Immunoblotting
HSC-3 cells were washed twice with D-PBS and extracted on ice
in a RIPA Lysis Buffer (2 mM PMSF, 1 mM sodium orthovanadate,
protease inhibitor cocktail, 1 mM EDTA, lysis buffer, pH 7.4), and
then centrifuged at 14,000 g for 15 min at 4 C. HSC-3 whole-cell
lysates were incubated for 5 min at 100 C in a 1:1 (v:v) ratio of
TriseSDS b-ME sample solution and electrophoresed on 10% SDS
gel with molecular weight standards. Proteins separated on 10%
SDSePAGE were transferred to PVDF membranes using by the
Trans-Blot® Turbo™ Transfer System. After protein transfer, the
membrane was blocked with Detector Block Solution overnight at
4 C. Membranes were then incubated with 1 mg/mL rabbit anti-
CTL1 polyclonal antibody (ab110767) and 0.5 mg/mL anti-CTL2
monoclonal antibody (clone 3D11) in new Detector Block Solution
overnight at 4 C. Membranes were then washed three times in
wash solution and incubated with 1 mg/mL horseradish peroxidase-
conjugated anti-rabbit and anti-mouse IgG for 1 h at room tem-
perature. Membranes were washed with wash solution and protein
bands were visualized using an ECL Prime Western Blotting
Detection System (GE Healthcare Life Sciences, Marlborough, MA,
USA). The luminescent image was obtained using a ChemiDoc XRS
Plus System (Bio-Rad Laboratories, Hercules, CA, USA).
2.6. Immunocytochemistry
HSC-3 cells grown on a 35 mm Glass Base dish (IWAKI, Japan)
were washed twice with D-PBS and ﬁxed with 100% methanol for
20 min at room temperature. Cells were permeabilized with D-PBS
containing 0.2% Triton X-100 for 5 min. Fixed cells were incubated
with Detector Blocking Solution overnight at 4 C. Cells were
incubatedwith 2 mg/mL rabbit anti-CTL1 polyclonal antibody and 1/
100 anti-pan cadherin antibody in new blocking solution overnight
at 4 C. The co-localization of CTL2 and mitochondria, ER and Golgi
was conﬁrmed using the organella marker antibody. Primary
antibody reactions for the following antibodies were performed for
4 h at room temperature: (I) anti-CTL2mousemonoclonal antibody
(4 mg/mL), (II) anti-COX IV polyclonal antibody (3 mg/mL), (III) anti-
Calnexin polyclonal antibody (2 mg/mL) and (IV) anti-MG130
polyclonal antibody (1:250). After being washed with wash solu-
tion, the cells were incubated with 2 mg/mL Alexa Fluor 488 goat
anti-rabbit IgG, 2 mg/mL Alexa Fluor 488 goat anti-mouse IgG, 2 mg/
mL Alexa Fluor 568 goat anti-mouse IgG and 2 mg/mL Alexa Fluor
568 goat anti-rabbit IgG for 1 h at room temperature. After excess
antibody was washed out with wash solution, the specimens were
mounted using VECTASHIELD mounting medium with DAPI. Fluo-
rescence images were obtained with a Confocal Laser Scanning
Biological Microscope (FV10i-DOC, Olympus, Japan).
2.7. Cell viability assay
Cells were plated at 5  104 cells per well in 24-well plates.
Inhibitors were added 24 h after cell plating, and the ﬁnal volume of
medium in each well was 1.0 mL. Cell numbers were measuredusing an ATPLite™, and the luminescence ATP detection assay
system was used as described in the manufacturer's instructions.
Luminescence was measured on a FilterMax F5 Multi-Mode
Microplate Reader (Molecular Devices, LLC, Sunnyvale, CA, USA).
2.8. Measurement of caspase 3 and 7 activity
For measurement of the activities of caspases 3 and 7, the Cas-
pase-Glo® 3/7 Assay was carried out according to the manufac-
turer's instructions. This kit is based on the cleavage of the DEVD
sequence of a luminogenic substrate by caspases 3 and 7, resulting
in a luminescent signal. HSC-3 cells were seeded at a density of
5  104 cells/well in 24-well plates. Test drugs were added 24 h
after cell plating, and the ﬁnal volume of medium in each well was
1.0 mL. The activities of caspases 3 and 7 were measured after drug
administration using a Caspase-Glo® 3/7 Assay kit. Luminescence
was measured on a FilterMax F5 Multi-Mode Microplate Reader.
2.9. Apoptotic/necrotic/healthy cell detection assay
Apoptotic, necrotic, and healthy cells were detected using an
apoptotic/necrotic/healthy cell detection kit (PromoCell, Heidel-
berg, Germany) according to the manufacturer's instructions. Cells
were cultured with the deﬁned medium D-MEM with 30 mM
choline chloride (Normal) or without choline chloride (choline
deﬁciency: CD) for 4 h, and then stained with Hoechst 33342 (blue,
nucleus), FITC-annexin V (green) and ethidium homodimer III
(EthD-III: red) for 15 min. Fluorescence images were obtained with
a Confocal Laser Scanning Biological Microscope (FV10i-DOC,
Olympus, Japan).
2.10. Data analysis
Data are expressed as means ± SD. Statistical analyses were
performed with the unpaired t-test and Dunnett's multiple com-
parisons test using the commercially available software Prism 6
(GraphPad Software, Inc., San Diego, CA, USA). The results were
considered to be statistically signiﬁcant when p-values were less
than 0.05. Kinetic parameters were calculated by non-linear
regression methods using Prism 6. Ki values were derived from
IC50 values as described by Cheng and Prusoff (13): Ki¼ IC50/(1þ[L]/
Km), where [L] is the concentration of radiolabeled ligand.
3. Results
3.1. Expression of mRNA and protein for choline transporters in
HSC-3 cells
The expression of mRNA for CHT1, CTL1-5 and OCT1-3 was
investigated by real-time PCR analysis (Fig. 1A). CTL1 and CTL2
mRNAs were highly expressed, while CHT1, CTL4, CTL5 and OCT2
mRNAs were not expressed in HSC-3 cells. CTL3, OCT1 and OCT3
mRNAs were expressed at a low level.
CTL1 and CTL2 mRNA were mainly expressed in HSC-3 cells by
real-time PCR analysis. Therefore, we examined the expression of
CTL1 and CTL2 at the protein level using western blot analysis.
Immunoblot assayswith CTL1 and CTL2 antibody demonstrated the
presence of bands of 70 kDa and 60 kDa, respectively (Fig. 1B).
The subcellular distribution of CTL1 and CTL2 in HSC-3 cells was
determined by immunocytochemical staining (Fig. 1C). CTL1
immunoreactivity was detected predominantly on the cell surface
and overlapped that of the plasmamembranemarker pan Cadherin.
On the other hand, CTL2 immunoreactivity was recognized in
intracellular compartments, and overlapped that of the
Fig. 1. Expression of mRNA and protein for choline transporters in HSC-3 cells. (A) Real-time PCR analysis of the expression of mRNAs for CHT1, CTL1-5, and OCT1-3. Relative mRNA
expression is expressed as a ratio of the target mRNA to GAPDHmRNA. Experiments were performed in triplicate. Each column represents the mean ± S.D. (n ¼ 3). BLQ means below
the limit of quantiﬁcation. (B) Detection of CTL1 and CTL2 proteins by western blot analysis. MM, pre-stained protein molecular weight marker. (C) Subcellular distribution of CTL1
and CTL2 proteins by immunocytochemistry. Fluorescence from antibodies directed to CTL1 (green), pan Cadherin (red), CTL2 (green), COV IV (red), Calnexin (red) and MG130 (red)
was imaged with a confocal microscope. Nuclei are stained with DAPI (blue). Merged images are shown in Merge, and yellow represents co-localization. Low: low magniﬁcation.
High: high magniﬁcation.
R. Nishiyama et al. / Journal of Pharmacological Sciences 131 (2016) 101e109104mitochondrial marker COX IV. However, the immunoreactivity of
CTL2 did not overlap that of the ER marker Calnexin or the Golgi
marker MG130.3.2. Time course, Naþ-dependency and kinetics of [3H]choline
uptake into HSC-3 cells
We examined the time course of [3H]choline uptake at a con-
centration of 10 mM in the presence and absence of extracellular
Naþ inHSC-3 cells (Fig. 2A). [3H]Cholineuptake increased in a time-
dependent manner, and was linear with time for at least up to
20min.When NaCl in the uptake buffer was replaced by NMDG-Cl,
the uptake of [3H]choline under Naþ-free conditionswas increased
compared to the control uptake under normal conditions.The characteristics of the kinetics of [3H]choline uptake into
HSC-3 cells were determined (Fig. 2B). A kinetic analysis of [3H]
choline uptake, as computed by nonlinear regression analysis,
yielded a MichaeliseMenten constant (Km) of 3.5 ± 0.4 mM and a
maximal velocity (Vmax) of 186.9 ± 7.4 pmol/mg protein/h. The
participation of a single process in [3H]choline uptake was sug-
gested based on a linear Eadie-Hofstee plot (Fig. 2B, inset). These
data suggest that [3H]choline uptake into HSC-3 cells is mediated
by a single intermediate-afﬁnity transport system.
3.3. Properties of [3H]choline uptake in HSC-3 cells
It has been reported that choline uptake through CTL1 is
completely inhibited by HC-3 in the mM range (9). We investigated
the inhibitory effects of HC-3 on the uptake of [3H]choline into HSC-
Fig. 2. Time course and Naþ-dependence of [3H]choline uptake in HSC-3 cells. (A)
Time course of 10 mM [3H]choline uptake in the presence (C) and absence (▫) of
extracellular Naþ for 60 min. Naþ-free buffer was modiﬁed by replacing NaCl with an
equimolar concentration of NMDG-Cl. The time-course of [3H]choline uptake was
ﬁtted to the experimental data by a non-linear regression analysis. Each point repre-
sents the mean ± S.D. (n ¼ 4). (B) Kinetic characteristics of [3H]choline uptake in HSC-3
cells. Cells were incubated for 20 min with [3H]choline at concentrations of
2.3e17.5 mM. Each point represents the mean ± S.D. (n ¼ 4). The speciﬁc uptake of [3H]
choline was calculated as the difference between total [3H]choline uptake in the
presence (nonspeciﬁc uptake) and absence (total uptake) of 30 mM unlabeled choline.
An analysis of the kinetics of [3H]choline uptake (speciﬁc uptake), as computed by a
non-linear regression analysis, yielded a Km of 3.5 ± 0.4 mM, and a Vmax of
186.9 ± 7.4 pmol/mg protein/h. Inset: Eadie-Hofstee plots of [3H]choline uptake show
single straight lines.
Fig. 3. Properties of [3H]choline uptake in HSC-3 cells. (A) Effects of HC-3 on [3H]
choline uptake in HSC-3 cells. Cells were pre-incubated with various concentrations of
HC-3 for 20 min, and the uptake of 10 mM [3H]choline was then measured for 20 min.
Results are given as a percentage of the control uptake measured in the presence of
vehicle. The Ki value of HC-3 for the inhibition of [3H]choline uptake was 2.1 mM. Each
point represents the mean ± S.D. (n ¼ 4). (B) Inﬂuence of extracellular pH on [3H]
choline uptake in HSC-3 cells. The uptake of 10 mM [3H]choline was measured for
20 min under different pH conditions. The results show [3H]choline uptake as a per-
centage of that at pH 7.5. Each column represents the mean ± S.D. (n ¼ 4). *p < 0.05
and ***p < 0.001 compared with pH 7.5.
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concentration-dependent manner. The Ki value for the inhibition of
[3H]choline uptake by HC-3 was 2.1 mM.
It has been reported that choline uptake through CTL1 is pH-
dependent (9). Therefore, the effect of extracellular pH on the up-
take of [3H]choline in HSC-3 cells was examined by varying the pH
of the pre-incubation media between pH 6.0 and 8.5 (Fig. 3B). [3H]
Choline uptake signiﬁcantly decreased when the extracellular pH
was changed from 7.5 to 6.0, and was signiﬁcantly enhanced when
the pH of the extracellular medium was changed from 7.5 to 8.5.3.4. Effects of various cationic drugs on [3H]choline uptake and cell
viability in HSC-3 cells
It is well known that OCTs and CTL1 recognize a multitude of
endogenous and exogenous organic cations as substrates and
exhibit considerable overlap in substrate speciﬁcity (9). We inves-
tigated the inhibitory effects of 25 cationic drugs (100 mM) on the
uptake of [3H]choline and cell viability in HSC-3 cells (Fig. 4A).Several cationic drugs inhibited cell viability and [3H]choline up-
take. However, some cationic agents (alimemazine, bepridil,
ﬂuoxethine, promethazine, tranilast) that inhibited choline trans-
port did not affect cell viability. We examined the effects of 10 drugs
(clemastine, cyproheptadine, ebastine, ﬂuvoxamine, homo-
chlorcyclizine, lomerizine, loratazine, mequitazine, oxatomide, and
rupatadine, which are surrounded by a circle in Fig. 4B) that
inhibited both cell viability and [3H]choline uptake on caspase-3/7
activity. These drugs inhibited cell viability and increased caspase-
3/7 activity in HSC-3 cells (Fig. 5).
3.5. Choline deﬁciency induces apoptosis in HSC-3 cells
We assessed whether choline deﬁciency-induced cell death
occurs through necrosis or apoptosis (Fig. 6A). Membrane-
permeable Hoechst 33342 (blue) stains the nuclei of both
apoptotic and necrotic cells. However, healthy cells are stained only
by Hoechst 33342, and not by FITC-Annexin V (green) or EthD-III
(red). Early apoptotic cells are stained both green and blue.
Necrotic cells are stained both red and blue. Cells stained with blue,
green and red are dead cells progressing from the apoptotic cell
population (late apoptotic cells), or necrotic cells. Most of the HSC-3
cells cultured in normal medium only showed staining by Hoechst
33342. In choline deﬁciency (CD), cells were stained with FITC-
Fig. 4. Effects of 25 cationic drugs on [3H]choline uptake and cell viability in HSC-3
cells. (A) Cells were incubated with 100 mM cationic drugs for 20 min, and then
10 mM [3H]choline uptake was measured. Results are given as a percentage of the
control uptake measured in the presence of vehicle. Each point represents the
mean ± S.D. (n ¼ 3). Cell viability was measured 24 h after treatment with 100 mM
cationic drug. Cell numbers were measured using an ATPLite™. Results are given as a
percentage of the ﬁndings in the vehicle control. Each column represents the
mean ± S.D. (n ¼ 3). (B) A correlation analysis of the potencies of various cationic drugs
(100 mM) for the inhibition of [3H]choline uptake and cell viability (data from Fig. 4A).
We selected 10 drugs (which are surrounded by a circle in Fig. 4B), including clem-
astine, cyproheptadine, ebastine, ﬂuvoxamine, homochlorcyclizine, lomerizine, lor-
atadine, mequitazine, oxatomide, and rupatadine, that inhibited both cell viability and
[3H]choline uptake.
Fig. 5. Effects of 10 cationic drugs that inhibited both cell viability and [3H]choline
uptake on cell viability and caspase-3/7 activity in HSC-3 cells. Cells were incubated
with 100 mM cationic drugs for 4 h. Cell numbers and caspase-3/7 activity were
measured using an ATPLite™ and the Caspase-Glo® 3/7 Assay. Results are given as a
percentage of the ﬁndings in the vehicle control. Each column represents the
mean ± S.D. (n ¼ 4).
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together with EthD-III.
We investigated the inﬂuence of choline deﬁciency on cell
viability and caspase-3/7 activity in HSC-3 cells (Fig. 6B). Cells were
seeded at 5  104 cells/mL/well on 24-well culture plates and
incubated in deﬁned medium D-MEMwith 30 mM choline chloride
(Normal) or without choline chloride (choline deﬁciency: CD) for 2
days. Choline deﬁciency signiﬁcantly inhibited cell viability and
signiﬁcantly increased caspase-3/7 activity in HSC-3 cells.4. Discussion
Choline PET and MRS have shown that enhanced choline
transport may play a role in the elevation of choline and choline
metabolites in tongue cancer cells (3,4). The elevation of total
Fig. 6. Choline deﬁciency induces apoptosis in HSC-3 cells. (A) Cells were cultured with the deﬁned medium D-MEM with 30 mM choline chloride (Normal) or without choline
chloride (choline deﬁciency) for 4 h, and then stained with Hoechst 33342 (blue, nucleus), FITC-annexin V (green) and ethidium homodimer III (EthD-III: red) for 15 min. Merged
images are shown in Merge. Arrow and asterisks show FITC-annexin V-positive and both FITC-annexin V- and EthD-III-positive cells, respectively. Low: low magniﬁcation. High:
high magniﬁcation. (B) Inﬂuence of choline deﬁciency on cell viability and caspase-3/7 activity. Cells were seeded at 1  104 cells/mL/well on 24-well culture plates and incubated in
deﬁned medium D-MEM with 30 mM choline chloride (Normal) or without choline chloride (choline deﬁciency: CD) for 2 days. Cell numbers and caspase-3/7 activity were
measured using an ATPLite™ and the Caspase-Glo® 3/7 Assay. Each column represents the mean ± S.D. (n ¼ 4). **p < 0.01 and ****p < 0.0001 compared with the normal conditions.
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and SAM is one of the most widely established characteristics of
cancer cells. The intracellular accumulation of choline through
choline transporters is the rate-limiting step in cell membrane
synthesis and DNA methylation. It is important that we charac-
terize the underlying mechanism and the expression of choline
transport systems in tongue cancer cells.
We ﬁrst examined the expression of mRNA for CHT1, CTL1-5 and
OCT1-3 in HSC-3 cells by real-time RT-PCR analysis. We found that
CTL1 and CTL2 mRNA were mainly expressed in HSC-3 cells.
Furthermore, both CTL1 and CTL2 proteins were expressed, and
were localized in the plasma membrane and mitochondria,
respectively. These results indicate that CTL1 may be involved in
the uptake of extracellular choline into cells. On the other hand,
CTL2 participates in choline transport in mitochondria. Cholineoxidation occurs in the matrix of mitochondria in the liver and
kidney (13), which shows that intracellular choline must cross the
mitochondrial membrane before oxidation can occur. Interestingly,
choline-deﬁciency causes mitochondrial and cellular oxidative
damage and lipid peroxidation (14). Thus, choline is also an
essential substance for mitochondria. We suggest that CTL2 might
be the major site for the control of choline oxidation in mito-
chondria and hence for the supply of endogenous betaine and SAM.
Functional characterization studies have been performed with
CTL1 in colon and lung cancer, and have shown that CTL1 is a Naþ-
independent, intermediate-afﬁnity transporter of choline that can
be completely inhibited by HC-3 in the mM range (15,16). In this
study, we found that HSC-3 cells take up [3H]choline by a saturable
process that is mediated by a single and Naþ-independent trans-
port system. The Km values were 3.5 mM, which is very close to the
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ters were very similar to those in the human colon carcinoma cell
line HT-29 (15) and the neuroblastoma cell lines SH-SY5Y and LA-
N-2 (17), and these cell types showed a property like CTL1. CHT1
and CTL1 functions are selectively inhibited by HC-3 at nM and mM
ranges, respectively (9). The Ki value of HC-3 for HSC-3 cells is
2.1 mM, which is very close to the Ki value for CTL1. These ﬁndings
strongly suggest that CTL1, but not CHT1, plays a role in the uptake
of choline by HSC-3 cells. Interestingly, a very similar pH proﬁle
(pH-dependent uptake) was observed for choline transport in colon
carcinomas, glioblastoma cells, and small cell lung carcinoma,
which is mediated by CTL1 (15,16,18). [3H]Choline uptake in HSC-3
cells was decreased by acidiﬁcation and increased by alkalinization
of the extracellular medium, indicating that choline may be
transported by a choline/Hþ antiport system. Moreover, removal of
Naþ from the uptake buffer strongly enhanced [3H]choline uptake
in HSC-3 cells. The absence of Naþ in uptake buffer stimulates
reverse-mode Naþ/Hþ exchangers (NHEs), which results in an in-
crease in the concentration of intracellular Hþ, and this Hþ gradient
in turn accelerates the choline transport mediated by choline/Hþ
antiporter. The potentiation of choline uptake under Naþ-free
conditions is not observed in normal cells (19e21). Thus, the
function of choline transporter CTL1 in co-operation with NHEs
might be a distinctive characteristic of cancer cells.
Many studies have reported that various organic cations
inhibited choline uptake (19,22). A correlation analysis of the po-
tencies of organic cations for the inhibition of choline uptake and
cell viability showed a strong correlation in lung cancer cells (16).
Thus, these results indicate that there is a strong correlation be-
tween cell survival and the inhibition of choline uptake. In addition,
the inhibition of CTL1 mRNA expression by CTL1 siRNA inhibited
[3H]choline uptake and cell viability, and increased caspase-3/7
activity in small cell lung carcinoma cells (16). These results
demonstrate that the functional inhibition of CTL1 could promote
apoptotic cell death. We explored the possible correlation between
choline uptake and cell viability by examining the effects of 25
cationic drugs on the survival of HSC-3 cells. We found that several
cationic drugs inhibited cell viability and [3H]choline uptake. It may
be possible to induce cell death by obstructing the function of
choline uptake through CTL1 in tongue cancer cells. Another pos-
sibility is that organic cations are transported by CTL1 at the plasma
membrane, where they inﬂuence mitochondrial CTL2 and induce
cell death. However, some drugs did not show a correlation be-
tween choline uptake and cell viability. These drugs may have
different mechanisms for promoting cell death. In addition, some
cationic agents that inhibited choline transport did not affect cell
viability. These drugs might not induce cell death because they not
produced a prolonged inhibition of choline uptake. Choline uptake
inhibitors can inhibit HSC-3 cell viability, and increase caspase-3/7
activity. We further investigated the relationship between
apoptotic cell death and the inhibition of intracellular choline up-
take in HSC-3 cells. Cells cultured with choline-deﬁciency medium
that were stained with FITC-annexin V, either alone or together
with EthD-III, were apoptotic cells in either the early or late stages,
respectively. Furthermore, we found that choline deﬁciency
signiﬁcantly inhibited cell viability, and signiﬁcantly increased
caspase-3/7 activity. We concluded that the choline deﬁciency in
HSC-3 cells caused apoptotic cell death. However, we cannot
exclude the contribution of necrosis. These results demonstrate
that the functional inhibition of choline uptake through CTL1 could
promote apoptotic cell death. Previous studies have shown that
choline deﬁciency triggers apoptosis via a p53-independent
pathway (23) and increases the amount of ceramide, a lethal
metabolite, in PC12 cells and primary neurons (24,25). An increase
in ceramide was associated with choline deﬁciency-inducedapoptosis. The inhibition of choline transport decreased PCho and
PC contents; cancer cells attempt to overcome this by activating an
alternative mechanism for generating PCho and PC. This enables
cancer cells, to some extent, to continue PCho and PC production,
but also leads to the production of ceramide, which promotes
apoptosis. Aberrations in methylation play a causal role in a variety
of diseases, including cancer. Recent studies have established that,
like mutation, methylation-mediated gene silencing often leads to
tumor genesis (26). DNA methyltransferase inhibitors, such as 5-
azacytidine, reduce DNA methylation and reactivate abnormally
suppressed gene expression, which leads to clearing of the
neoplasm clones by various mechanisms (27). Our results suggest
that the functional inhibition of CTL2 in mitochondria, which leads
to the inhibition of betaine and SAM synthesis, and DNA methyl-
ation, may promote apoptotic cell death. The function of CTL2 may
be involved in an epigenetic mechanism in tongue cancer cells.
Therefore, transporters of CTL1 and CTL2 represent attractive and
promising targets for therapeutic and diagnostic applications
regarding tongue cancers.
Finally, tongue cancer is easy to approach directly through the
oral cavity. Also, this study used cultured tumor cells and conﬁrmed
cytotoxicity by applying the medications directly to the cells. This
suggests that it may be feasible to administer medications through
the use of an ointment or mouth rinse.
We conclude that HSC-3 cells express the choline transporter
CTL1 which uses a directed Hþ gradient as a driving force. The
functional inhibition of CTL1 by cationic drugs could promote
apoptotic cell death. Furthermore, CTL2 may be the major site for
the control of choline oxidation in mitochondria and hence for the
supply of endogenous betaine and SAM, which serves as a major
methyl donor. The functional inhibition of CTL2 may also promote
apoptotic cell death. Identiﬁcation of this CTL1- and CTL2-mediated
choline transport system provides a potential new target for tongue
cancer therapy.
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